Work

PROPEL: A randomized phase III trial evaluating the efficacy and safety of olaparib combined with abiraterone as first-line therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)

Year: 2019

Type: conference-abstract

Source: European Urology Supplements

DOI: 10.1016/s1569-9056(19)31321-1

Authors: N.W. Clarke, A.J. Armstrong, A. Thiery-Vuillemin, M. Oya, D. Ye, J. Mateo, C. Goessl, J. Kang, S. Liu, F. Saad

Institutions: Duke University, Duke Medical Center, Duke Cancer Institute, Centre Hospitalier Universitaire de Besançon, Keio University, Fudan University Shanghai Cancer Center, Vall d'Hebron Institute of Oncology, Centre Hospitalier de l’Université de Montréal, Université de Montréal

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2922527638

Cites:

Cited by: 1

Related to: 10